echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Movement disorders: Serum microRNAs predict isolated REM sleep behavior disorder and Lewy body disease

    Movement disorders: Serum microRNAs predict isolated REM sleep behavior disorder and Lewy body disease

    • Last Update: 2022-10-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by a lack of REM sleep-related muscle atony, uninhibited motor activity, and dream behavior


    Figure 1: Paper cover image


    In this study, Marta Soto et al.


    Cross-sectionally, they identified novel differentially expressed miRNAs (DEmiRs) associated with IRBD and α-synucleinopathy, which were subsequently validated using three longitudinal follow-up serum samples of DaT-negative and DaT-positive IRBD



    Using genome-wide miRNA profiling and real-time quantitative PCR should be validated, they assessed serum miRNA profiles in IRBD patients stratified by dopamine transporter (DaT) single-photon emission computed tomography for DaT-negative IRBD (n = 17) and DaT-positive IRBD (n = 21), IRBD-appearance converted to LBD (n = 13), and controls (n = 20)


    Longitudinal, they followed the IRBD cohort by studying serum samples at three time points over a 26-month period


    Figure 2: The results of the paper

    They found persistent cross-sectional and longitudinal deregulation of 12 miRNAs across the RBD continuum, including DaT-negative IRBD, DaT-positive IRBD, and LBD-phenotype-switched IRBD (let-7c-5p.


    Age- and sex-adjusted predictive models based on 12 differentially expressed miRNA biosignatures differentiated IRBD and PD or DLB from controls with an area under the curve of 98% (95% confidence interval: 89–99%)


    The significance of this study lies in the discovery that: In addition to clinical diagnosis of IRBD or imaging markers such as DaT single photon emission computed tomography, specific miRNA biosignatures alone hold promise as biomarkers of progression in IRBD patients to predict PD and DLB clinical results


    In other high-risk PD populations, such as asymptomatic carriers of LRRK2 mutations or subjects with hypoglycemia, further miRNA studies are warranted


    Original source:


     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.